Vasilios C Constantinides1, George P Paraskevas2, Evangelia Emmanouilidou3, Olga Petropoulou2, Anastasia Bougea2, Kostas Vekrellis3, Ioannis Evdokimidis2, Eleftherios Stamboulis2, Elisabeth Kapaki2. 1. 1st Department of Neurology, National and Kapodistrian University of Athens, Eginition Hospital, 72-74 Vassilisis Sofias Avenue, Athens P.C.:11528, Greece. Electronic address: vconstan@med.uoa.gr. 2. 1st Department of Neurology, National and Kapodistrian University of Athens, Eginition Hospital, 72-74 Vassilisis Sofias Avenue, Athens P.C.:11528, Greece. 3. Division of Basic Neurosciences, Biomedical Research Foundation, Academy of Athens, 4 Soranou Ephessiou Street, Athens P.C. 11527, Greece.
Abstract
INTRODUCTION: Differential diagnosis of Parkinson-plus patients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - Aβ42, tau protein - τT and phosphorylated tau protein - τP-181) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism. The aim of this study was to analyze the CSF biochemical profile of patients with Parkinsonism. METHODS: We analyzed the CSF biomarker profile (Aβ42, τT, τP-181, α-syn) and all relevant ratios in 68 patients with Parkinsonism (19 PSP, 15 MSA, 17 CBD, 17 PD) and 18 controls, diagnosed by latest established diagnostic criteria. RESULTS: CBD patients exhibited elevated τT and decreased Aβ42 compared to the other groups. Five CBD, one PSP patient and one control had a typical AD CSF profile. After exclusion of these patients, the τT/Aβ42 ratio was significantly elevated in MSA patients compared to PD patients and provided excellent specificity and adequate sensitivity in their differential diagnosis. CONCLUSION: CSF biochemical profile analysis is important in distinguishing AD patients with a CBS phenotype from non-AD CBS patients. The τT/Aβ42 ratio is useful in the differential diagnosis of MSA from PD.
INTRODUCTION: Differential diagnosis of Parkinson-pluspatients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - Aβ42, tau protein - τT and phosphorylated tau protein - τP-181) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism. The aim of this study was to analyze the CSF biochemical profile of patients with Parkinsonism. METHODS: We analyzed the CSF biomarker profile (Aβ42, τT, τP-181, α-syn) and all relevant ratios in 68 patients with Parkinsonism (19 PSP, 15 MSA, 17 CBD, 17 PD) and 18 controls, diagnosed by latest established diagnostic criteria. RESULTS: CBD patients exhibited elevated τT and decreased Aβ42 compared to the other groups. Five CBD, one PSPpatient and one control had a typical AD CSF profile. After exclusion of these patients, the τT/Aβ42 ratio was significantly elevated in MSA patients compared to PDpatients and provided excellent specificity and adequate sensitivity in their differential diagnosis. CONCLUSION: CSF biochemical profile analysis is important in distinguishing ADpatients with a CBS phenotype from non-ADCBSpatients. The τT/Aβ42 ratio is useful in the differential diagnosis of MSA from PD.
Authors: Diego Castillo-Barnes; Javier Ramírez; Fermín Segovia; Francisco J Martínez-Murcia; Diego Salas-Gonzalez; Juan M Górriz Journal: Front Neuroinform Date: 2018-08-14 Impact factor: 4.081
Authors: Vasilios C Constantinides; Nour K Majbour; George P Paraskevas; Ilham Abdi; Bared Safieh-Garabedian; Leonidas Stefanis; Omar M El-Agnaf; Elisabeth Kapaki Journal: Brain Sci Date: 2021-01-17